Emerging Metabolic Therapies in Pulmonary Arterial Hypertension
Pulmonary hypertension (PH) is an enigmatic vascular disorder characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance, ultimately resulting in pressure overload, dysfunction, and failure of the right ventricle. Current medications for PH do not reverse or prevent d...
Main Authors: | Lloyd D. Harvey, Stephen Y. Chan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | http://www.mdpi.com/2077-0383/6/4/43 |
Similar Items
-
Sex Differences, Estrogen Metabolism and Signaling in the Development of Pulmonary Arterial Hypertension
by: Yanan Sun, et al.
Published: (2021-09-01) -
Pulmonary Arterial Stiffness: An Early and Pervasive Driver of Pulmonary Arterial Hypertension
by: Wei Sun, et al.
Published: (2018-07-01) -
Autonomous glucose metabolic reprogramming of tumour cells under hypoxia: opportunities for targeted therapy
by: Mingyao Huang, et al.
Published: (2020-09-01) -
Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
by: Dimas Carolina Belisario, et al.
Published: (2020-12-01) -
Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension
by: Stevan P. Tofovic, et al.
Published: (2019-12-01)